Stifel Maintains Buy on Deciphera Pharmaceuticals, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino maintains a Buy rating on Deciphera Pharmaceuticals (NASDAQ:DCPH) and raises the price target from $20 to $22.
October 31, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Bradley Canino maintains a Buy rating on Deciphera Pharmaceuticals and raises the price target from $20 to $22.
The news of Stifel maintaining a Buy rating and raising the price target for Deciphera Pharmaceuticals is likely to have a positive impact on the company's stock in the short term. Investors often follow analyst ratings and price targets, and this could lead to increased buying pressure for DCPH shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100